{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:10:16Z","timestamp":1785550216508,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.semcancer.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T12:01:05Z","timestamp":1496318465000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs"],"prefix":"10.1016","volume":"45","author":[{"given":"Lars","family":"Sandman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Liliemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2017.05.009_bib0005","unstructured":"Stepwise market approval of new pharmaceuticals. Principle of hope should not displace principle of safety [press release]. GKV Spitzenverband web page: GKV Spitzenverband 2016."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0010","series-title":"Conditional market authorisation","author":"EMA","year":"2017"},{"issue":"3","key":"10.1016\/j.semcancer.2017.05.009_bib0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpt.59","article-title":"From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients","volume":"97","author":"Eichler","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0020","first-page":"3","article-title":"Cancer drugs, survival, and ethics","volume":"355","author":"Wise","year":"2016","journal-title":"BMJ-Br. Med. J."},{"issue":"8","key":"10.1016\/j.semcancer.2017.05.009_bib0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejim.2015.08.008","article-title":"Approvals of drugs with uncertain benefit-risk profiles in Europe","volume":"26","author":"Banzi","year":"2015","journal-title":"Eur. J. Intern. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2017.05.009_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-007-0296-2","article-title":"Haematological anticancer drugs in Europe: any added value at the time of approval?","volume":"63","author":"Bertele","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7023","key":"10.1016\/j.semcancer.2017.05.009_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn't \u2212 it's about integrating individual clinical expertise and the best external evidence","volume":"312","author":"Sackett","year":"1996","journal-title":"Br. Med. J."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.breast.2016.06.005","article-title":"Surrogate end points for overall survival in breast cancer trials: a review","volume":"29","author":"Fiteni","year":"2016","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.semcancer.2017.05.009_bib0045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdw132","article-title":"Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer","volume":"27","author":"Michiels","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2017.05.009_bib0050","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.05.009_bib0055","series-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"2013"},{"issue":"3","key":"10.1016\/j.semcancer.2017.05.009_bib0060","first-page":"305","article-title":"On how to define the concept of health: a loose comparative approach","volume":"3","author":"Br\u00fclde","year":"2000","journal-title":"Med. Health Care Philos.: Eur. J."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0065","series-title":"The Concept of Work Ability","author":"Nordenfelt","year":"2008"},{"issue":"7","key":"10.1016\/j.semcancer.2017.05.009_bib0070","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0277-9536(00)00098-8","article-title":"Patient-centredness: a conceptual framework and review of the empirical literature","volume":"51","author":"Mead","year":"2000","journal-title":"Social Sci. Med."},{"issue":"8","key":"10.1016\/j.semcancer.2017.05.009_bib0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15265161.2013.802060","article-title":"Treating patients as persons: a capabilities approach to support delivery of person-centred care","volume":"13","author":"Entwistle","year":"2013","journal-title":"Am. J. Bioethics: AJOB"},{"key":"10.1016\/j.semcancer.2017.05.009_bib0080","series-title":"WMA Declaration of Helsinki\u2013Ethical Principles for Medical Research Involving Human Subjects","author":"WMA","year":"2016"},{"issue":"25","key":"10.1016\/j.semcancer.2017.05.009_bib0085","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJM198812223192504","article-title":"Assessing patients capacities to consent to treatment","volume":"319","author":"Appelbaum","year":"1988","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2017.05.009_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10728-008-0108-6","article-title":"Shared decision making, paternalism and patient choice","volume":"18","author":"Sandman","year":"2010","journal-title":"Health Care Anal."},{"issue":"1","key":"10.1016\/j.semcancer.2017.05.009_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10728-013-0242-7","article-title":"Challenges for principles of need in health care","volume":"23","author":"Juth","year":"2015","journal-title":"Health Care Anal."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0100","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.semcancer.2017.05.009_bib0105","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ejca.2013.01.015","volume":"49","author":"Dias","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.05.009_bib0110","series-title":"Assessment Report For Tyverb","author":"EMA","year":"2008"},{"issue":"9","key":"10.1016\/j.semcancer.2017.05.009_bib0115","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.semcancer.2017.05.009_bib0120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects systematic review and meta-regression analysis","volume":"303","author":"Bassler","year":"2010","journal-title":"JAMA-J. Am. Med. Assoc."},{"issue":"16","key":"10.1016\/j.semcancer.2017.05.009_bib0125","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.ejca.2011.05.019","article-title":"Early stopping rules in oncology: considerations for clinicians","volume":"47","author":"Mukherjee","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2017.05.009_bib0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0962280211432211","article-title":"Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?","volume":"22","author":"Bassler","year":"2013","journal-title":"Stat. Methods Med. Res."},{"issue":"9","key":"10.1016\/j.semcancer.2017.05.009_bib0135","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0277-9536(03)00338-1","article-title":"Therapeutic misconception and the appreciation of risks in clinical trials","volume":"58","author":"Lidz","year":"2004","journal-title":"Social Sci. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2017.05.009_bib0140","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00520-013-1891-7","article-title":"Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation","volume":"21","author":"Godskesen","year":"2013","journal-title":"Support. Care Cancer"},{"issue":"9405","key":"10.1016\/j.semcancer.2017.05.009_bib0145","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(03)15383-4","article-title":"Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review","volume":"363","author":"Peppercorn","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semcancer.2017.05.009_bib0150","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.healthpol.2007.09.001","article-title":"Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom","volume":"85","author":"Milewa","year":"2008","journal-title":"Health Policy"},{"issue":"6","key":"10.1016\/j.semcancer.2017.05.009_bib0155","doi-asserted-by":"crossref","first-page":"A272","DOI":"10.1016\/S1098-3015(10)63421-3","article-title":"A review of factors affecting therapeutic compliance","volume":"9","author":"Jin","year":"2006","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.semcancer.2017.05.009_bib0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10897-009-9227-y","article-title":"Risk perception among women at risk for hereditary breast and ovarian cancer","volume":"18","author":"Pilarski","year":"2009","journal-title":"J. Genet. Couns."},{"issue":"6","key":"10.1016\/j.semcancer.2017.05.009_bib0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1037\/a0017327","article-title":"How numeracy influences risk comprehension and medical decision making","volume":"135","author":"Reyna","year":"2009","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.semcancer.2017.05.009_bib0170","doi-asserted-by":"crossref","unstructured":"Prioriteringar inom h\u00e4lso- och sjukv\u00e5rden, Proposition 1996\/97:60 (1996\/97:60).","DOI":"10.1007\/BF02308885"},{"issue":"1","key":"10.1016\/j.semcancer.2017.05.009_bib0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10728-016-0333-3","article-title":"The (Ir)relevance of group size in health care priority setting: a reply to Juth","volume":"25","author":"Sandman","year":"2016","journal-title":"Health Care Anal."},{"issue":"2","key":"10.1016\/j.semcancer.2017.05.009_bib0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/phe\/phr013","article-title":"Reasons why post-trial access to trial drugs should, or need not be ensured to research participants: a systematic review","volume":"4","author":"Sofaer","year":"2011","journal-title":"Public Health Ethics"},{"issue":"11","key":"10.1016\/j.semcancer.2017.05.009_bib0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","article-title":"Using value of information analysis to prioritise health research \u2013 some lessons from recent UK experience","volume":"24","author":"Claxton","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semcancer.2017.05.009_bib0190","article-title":"Betalningsviljan f\u00f6r nya l\u00e4kemedel bygger p\u00e5 etiska principer. NT-r\u00e5det tolkar riksdagens plattform f\u00f6r prioritering","volume":"113","author":"Liliemark","year":"2016","journal-title":"L\u00e4kartidningen"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T11:06:59Z","timestamp":1569409619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X17301372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":38,"alternative-id":["S1044579X17301372"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.05.009","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}